Record 25% growth masks flat profit; execution risk on leverage

Delivered ₹1387.9 Cr, +25.3% YoY, all regions and categories contributed

EBITDA margin 18.8% delivered vs 20% underlying target; management claims 19.6% underlying excluding pass-through

PAT ₹100.6 Cr down 0.8% YoY; contradicts double-digit full-year claim

Pricing recovered but PAT flat suggests downstream costs, capex, or tax absorbing margin expansion

EBITDA +15.2% YoY consistent with claim

From 11-13% (early double digits) to high teens. Drivers: B&C momentum, Oral Care recovery >20%, Thailand ramp-up.

Reaffirmed 20% underlying despite cost inflation. Q1 delivered 18.8%; management claims 19.6% underlying excluding pass-through pricing.

Reaffirmed double-digit full-year growth, but Q1 down 0.8% YoY. Credibility gap; management blamed ETR/phasing, not fundamentals.

Operations now ramping; described as 'really significant B&C market' and future growth driver.

New investments in production capability, printing centralization in Poland, front-end salesforce growth. Long-term payoff expected; near-term margin drag.

Primarily inventory: pricing of inventory rose with RM costs, plus safety stock for supply security. AR aging normal; quality solid.

Operational challenges identified, getting full team focus. Investments in capacity (extruded), printing (Poland centralization), B&C capability (die, tooling) for long-term. Margins to recover progressively.

High-teens revenue growth for next few quarters. Margins held 20% underlying. PAT on track double-digit full year; Q1 low due to ETR and phasing.

OpEx in line with plans. B&C center of excellence, divisional sales teams, embellishment investments ahead of curve. Underlying costs efficient; margins target 20%.

Oral normally high single-digit. 24% this Q from wallet/share gains during crisis via service reliability. Not every-quarter sustainable. B&C is growth lever; targeting share double from 8% to 16% over next few years.

Entire cost recovered via pricing. Blended contracts cover currency, freight, RM. Consumption cost has old inventory benefit, but pricing lag with few customers. Net-net, full recovery achieved.

Revenue still includes pricing impact. Underlying EBITDA margin higher. Investments in Brazil and U.S. capabilities (both capex and sales team split: Oral vs B&C) dragging reported margin.

ETR 18-22% range across multi-country operations (steady-state). Last year 18% (lower end), this year likely 20-22% depending on country profitability mix.

Cannot comment during approval phase (independent companies). Indovida's Q1 public results excellent: 25% revenue, 62% EBITDA growth, 27% margin, ₹383 Cr EBITDA. Post-merger will explore opportunities.

Raised from early double digits (11-13%). Drivers: B&C momentum, Oral recovery, Thailand ramp. Reaffirmed multiple times in Q&A.

Delivered 18.8% this Q; management claims 19.6% underlying excluding pass-through. Confidence in margin defense despite cost inflation and capex drag.

No specific ₹ amount disclosed. Impact visible in P&L: capex absorption depressing PAT leverage. Expected payoff as revenue scales.

PAT flat YoY (-0.8%) despite 25.3% revenue growth. PBT only +10%, implying capex depreciation, interest, or tax absorption of profit. Full-year double-digit PAT guidance at risk if trend persists.

Europe delivered 20.2% revenue growth but margins pressured. Management described 'operational challenges' identified and getting 'disproportionate focus', but no specifics on issues, magnitude, or recovery timeline provided.

Net debt rose partly due to ₹180 Cr working capital increase (inventory pricing + safety stock). If not unwound, constrains cash for capex, M&A, or shareholder returns. FY26 full-year WC increase was similar (₹170 Cr), suggesting structural build.

Long-term strategy (go beyond tubes, diversify into rigid plastics, expand emerging markets) pivots on Indovida acquisition. CCI approval received, but merger still pending final close. Unanticipated regulatory or integration hurdles could derail deal, resetting investor expectations.

Management claims 100% cost recovery (RM, freight, currency) via pricing this quarter. But history (post-COVID crisis) shows pricing lag and customer pushback are real. Elevated capex may absorb margin expansion. Geopolitical volatility (Middle East) ongoing; next shock could test pricing power.